Skip to content
  • ENGLISHENGLISH
  • 繁體中文繁體中文
回首頁回首頁回首頁
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder Services
    • Financials
    • Corporate Governance
  • Contact Us
MENU Close

2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual  Property Administration, Application No. 201780055635.3

2022/11/21 ALA-1000 received notice of patent allowance from China National Intellectual  Property Administration, Application No. 201780055635.3

  • Post author:alarpharm
  • Post published:21 . 11 . 2022
  • Post category:Media releases

You Might Also Like

2022/12/29 ALA -1300 Received notice of patent allowance from the Mexican Institute of Industrial Property (IMPI), NO: MX/a/2020/008471

1 . 2 . 2023

2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434.

9 . 8 . 2021

2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367.

3 . 5 . 2021

2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258.

12 . 11 . 2021

2022/05/12 ALA-1000 Received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI , Application No. 000487-2019/DIN.

13 . 5 . 2022
  • News
  • Event
  • Knowledge
回首頁

ABOUT

  • Company Profile
  • Leadership Team
  • History&Milestones
  • Company Profile
  • Leadership Team
  • History&Milestones

PRODUCTS

  • Products Pipeline
  • Contract Manufacturing
  • Products Pipeline
  • Contract Manufacturing

media

  • News
  • Event
  • Knowledge
  • News
  • Event
  • Knowledge

investors

  • Shareholder Services
  • Financials
  • Corporate Governance
  • Shareholder Services
  • Financials
  • Corporate Governance

CONTACT us

  • Contact Us
  • Contact Us
  • Contact Us
  • Privacy Policy
Copyright © - 2022 Alar Pharmaceuticals Inc . All right reserved.
Close
  • About Alar
    • Company Profile
    • Leadership Team
    • History&Milestones
  • Products
    • Products Pipeline
    • Contract Manufacturing
  • Media
    • News
    • Event
    • Knowledge
  • Investors
    • Shareholder
    • Financials
    • Corporate Governance
  • Contact Us
    • Contact Us
×

Cart